TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00862888

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 200mg dose as an oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Single oral dose 100 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 125 mg dose as an oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 175 mg dose as an oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00446687
Description: Single 20 mg dose as an oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Single oral dose 100 mg tablet
Study: NCT02406703

Intervention type: DRUG
Intervention: Chloroprocaine

Intervention type: DRUG
Intervention: Mepivacaine
Study: NCT00770354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS1402
Description: A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
Study: NCT02568527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PLGA scaffold
Description: Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
Study: NCT04545268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: NMES will carried out with four-channel myostimulator Beurer EM80 (Germany). Self-adhesive electrodes locates above the quadriceps, the duration of the NMES session was 60 minutes, including 5-minute periods of heating and hitch. Throughout the series, rectangular pulses with a frequency of 45 Hz will modulate. As a result, tonic contraction of these muscles will induce for 12 seconds, followed by a pause of 5 seconds. The amplitude of electrical exposure will select separately for each of the four channels until good muscle contraction (visually or by palpation) without pain. Electrical stimulation will start from the second day after the admission to preoperative department and will carried out during the entire preoperative period (about 10 days).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: For the Sham group, electrodes will follow the same site, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
Study: NCT03674229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive information about weight management programs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive information about weight management programs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone calls from an assigned patient navigator
Study: NCT00770354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Daily 2.5 mg oral letrozole tablet
Study: NCT04156867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynesys
Description: discectomy with Dynesys
Study: NCT04261517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments
Study: NCT04529161

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (FMD)
Description: The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet (FMD)
Description: The treatment consists in the self-administration of FMD at home - closely followed by the neuropsychologist by phone and by a properly trained nutritionist in the FMD sector - for 5 days a month for 6 consecutive months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routinary diet habits
Description: Subjects will follow their routinary eating habits for 6 consecutive months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routinary diet habits
Description: Subjects will follow their routinary eating habits for 6 consecutive months
Study: NCT03596060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be used for introduction in general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium will be used for introduction in general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirochaine
Description: Chirochaine 0.5% will be used in regional anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
Study: NCT04622358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-214-02
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-214-02
Description: 1 tablet administered before the breakfast during 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT04666987

Intervention type: DRUG
Intervention: Insulin degludec and liraglutide (IDegLira)
Description: Paricipants will be treated with commercially available Xultophy® according to routine clinical practice at the discretion of the treating physician, following approved label in Italy. The decision to initiate treatment with commercially available Xultophy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.
Study: NCT01268631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
Study: NCT02101944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV
Study: NCT01591096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator (Activase®)
Description: Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
Study: NCT02473172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Support ventilation
Description: Assisted mechanical ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Description: Assisted mechanical ventilation
Study: NCT01467713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL
Description: Ramelteon sublingual (SL) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL
Description: Ramelteon sublingual (SL) tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon SL
Description: Ramelteon sublingual (SL) tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon sublingual (SL) placebo-matching tablets
Study: NCT02661880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: preferred music
Description: listening to preferred music choices
Study: NCT03125252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundle
Description: Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~* thirst~* noise~* pain and well-being~* sleep~* isolation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Paramedical and Medical practices
Description: The current recommendations recommend the following scheme:~* Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~* Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~* Use of reference antipsychotic pharmacological means
Study: NCT03468517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bathe method:
Description: BATHE technique, on the other hand, is one of the short therapeutic consultation techniques that strengthen the doctor-patient relationship. BATHE stands for the initials of the questions that include the titles for Background, Affect, Trouble, Handling and Empathy. It allows evaluating the physiological stress of the patients quickly. BATHE method necessitates an empathetic expression that includes the view of the patient in addition to asking the key questions by the doctor doing the interview
Study: NCT01862718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal Ablation
Description: On Thursday in the first week, subject will receive the radiofrequency ablation.
Study: NCT00998920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: oral, BID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: oral, BID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: oral, BID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: oral, BID, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: oral, BID, 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, BID, 14 days
Study: NCT04622358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT05368818

Intervention type: OTHER
Intervention: Secukinumab
Description: Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source

Intervention type: OTHER
Intervention: Secukinumab
Description: Included patients treated with Cosentyx (Secukinumab) in a retrospective analysis of the BADBIR data source
Study: NCT03836690

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD62L- Tem
Description: Donor memory T cells that have been depleted of CD62L+
Study: NCT03867734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam
Description: 2g IM Aztreonam
Study: NCT01286259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Open label 500mg disulfiram per day by mouth for 14 days
Study: NCT00688805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 40 mg given as a single oral administration in an opaque capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching capsule containing no active medication
Study: NCT03839238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hESC derived MSC like cell
Description: Different dosage of hESC derived MSC like cell for the meniscus injured patients
Study: NCT02221115

Intervention type: DEVICE
Group type: OTHER
Intervention: Google Glass
Description: The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
Study: NCT02855905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise/Rest and cold/neutral temperature
Description: Subjects were either exercising or resting in either cold or neutral environmental temperature
Study: NCT03467659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cracked whole wheat porridge
Description: Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semolina wheat porridge
Description: Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole wheat flour porridge
Description: Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour porridge
Description: Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour porridge,fine bran
Description: Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour porridge,coarse bran
Description: Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
Study: NCT04388982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dosage MSCs-Exos administrated for nasal drip
Description: Dosage：5μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mild dosage MSCs-Exos administrated for nasal drip
Description: Dosage：10μg MSCs-Exos,Total volume： 1ml Frequency：Twice a week Duration：12 weeks
Study: NCT05243498

Intervention type: OTHER
Intervention: Assessment of the Allogenomic Mismatch Score (AMS)
Description: Allogenomic Mismatch Score (AMS) is a continuous variable based on the number of nsSNP between the donor and the recipient. Roughly, the exome of the donor is aligned to the exome of the recipient, allowing to count the number of variations that will generate a peptide present in the recipient but absent in the donor.
Study: NCT01862718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard External Beam Radiation Therapy
Description: During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
Study: NCT03086083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR standard protocol
Description: Patient have only one standard EMDR session about a traumatic situation remembered by him.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: protocol without brain stimulation
Description: Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
Study: NCT03296774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Beyond Pregnancy
Description: Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Study: NCT04626557

Intervention type: PROCEDURE
Intervention: biopsy
Description: biopsy of the endometrium

Intervention type: PROCEDURE
Intervention: biopsy
Description: biopsy of the endometrium
Study: NCT02953132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-4129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04619069

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to all sites of metastatic disease as seen on PSMA PET scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormone therapy
Description: Intermittent Hormone Therapy per physician discretion (Min. 8 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Description: Intermittent Hormone Therapy per physician discretion (Min. 8 months)
Study: NCT02918825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone
Study: NCT03840642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Me
Description: Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Me
Description: Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Coaching
Description: Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
Study: NCT01653223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months.
Study: NCT02521831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia (bupivacaine)
Description: Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (isoflurane)
Description: Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
Study: NCT00695981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotator cuff repair
Description: Rotator cuff repair + physical therapy according to a standardized protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Physiotherapy according to a standardized protocol
Study: NCT04184479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LEVAmethod by Bertz et al
Description: Ordinary treatment

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: LEVAmethod by Bertz et al
Description: Ordinary treatment
Study: NCT02915588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early isometric loading after rotator cuff surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: passive motion after rotator cuff surgery
Study: NCT00716586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide
Description: Carbonic anhydrase inhibitor, Trusopt (2% dorzolamide)